Statistically conclusive or suggested result Inconclusive results Uncertain results Safety results

es-BC - HER2 positive - (neo)adjuvant (NA) breast cancer - HER2-positive es-BC - HER2 positive - (neo)adjuvant (NA)

versus trastuzumab plus endocrine therapy
trastuzumab emtasine plus endocrine therapy vs. trastuzumab plus endocrine therapy 1 none-

suggested 4.0-fold increase in pCR but the degree if certainty is unassessable

-